Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMichael LaPelusaFLF. Anthony San LucasBIBryan Iorgulescu

Discussion

Loading...

Member takes

Overview

Pilot analysis demonstrates ctDNA clearance predicts pathologic complete response in localized dMMR/MSI-H CRC, suggesting its use as a biomarker.

Key Points

  • Pathologic complete response is predicted by ctDNA clearance after neoadjuvant immunotherapy in colorectal cancer.
  • Detection of baseline ctDNA occurred in 7 of 13 patients, with a median variant allele frequency of 8.5%.
  • The analysis employed a tumor-agnostic NGS-based ctDNA assay across 49 plasma samples collected serially from 13 patients.  PCR was observed in 6 of 6 patients without detectable ctDNA at baseline, compared to only 4 of 7 with detectable ctDNA.

Cite This Study

LaPelusa et al. (2024) studied this question.

synapsesocial.com/papers/68e671cdb6db6435875fc9bfhttps://doi.org/10.1200/jco.2024.42.16_suppl.3612
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract CT170: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction2026 · 1 citations
  2. 2Dynamic circulating tumor DNA profiling for prediction of long-term clinical benefit in pMMR locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy plus sintilimab.2026
  3. 3Abstract 1314: Circulating tumor DNA (ctDNA) clearance dynamics in microsatellite instability-high metastatic (MSI-H) colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).2026 · 1 citations
  4. 4Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis2026
  5. 5Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.2024 · 3 citations